Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, a drug called ado-trastuzumab
emtansine has on the patient and their cancer which is thought to be controlled by the
abnormal HER2 gene.